Bernstein: Straumann Set to Maintain 'Strong' Execution into H2; Price Target Up

05:32 AM EDT, 09/24/2026 (MT Newswires) -- Bernstein views Straumann Holding (STMN.SW) as set to sustain its solid operational momentum into the second half, even with ongoing macroeconomic and sectoral headwinds and a leadership change. "Straumann remains well positioned into H2 2026, with improving growth in North America helping address concerns around growth quality and dependence on China. Manufacturing optimization, cost initiatives and operating leverage continue to drive margin expansion, while dental implant VBP 2.0 is likely to prove manageable rather than disruptive. With iExcel, Neodent and Sirios supporting further market share gains and [currency] headwinds easing, Straumann looks set for continued strong execution," the research firm said Wednesday in a report focused on European consumer medical technology companies. Analysts noted that while Chief Executive Officer Guillaume Daniellot's departure created uncertainty, the transition strategy looks to be "well planned." Against this backdrop, Bernstein raised its price target on the stock to 124 francs from 122 francs and lifted its adjusted EPS forecasts for full-year 2026 and 2027 to 3.42 francs and 4.02 francs, respectively, from 3.40 francs and 3.89 francs. "We maintain our Outperform rating on Straumann as the company continues to demonstrate its strength as a high-quality operator in attractive end markets," the research firm wrote, adding the stock's recent near 10-year-low valuation serves as an "attractive" entry point.